268 related articles for article (PubMed ID: 29971469)
21. The effect of vitamin D and E vaginal suppositories on tamoxifen-induced vaginal atrophy in women with breast cancer.
Keshavarzi Z; Janghorban R; Alipour S; Tahmasebi S; Jokar A
Support Care Cancer; 2019 Apr; 27(4):1325-1334. PubMed ID: 30729333
[TBL] [Abstract][Full Text] [Related]
22. Management of vulvovaginal atrophy-related sexual dysfunction in postmenopausal women: an up-to-date review.
Tan O; Bradshaw K; Carr BR
Menopause; 2012 Jan; 19(1):109-17. PubMed ID: 22011753
[TBL] [Abstract][Full Text] [Related]
23. Randomized comparison of tolterodine with vaginal estrogen cream versus tolterodine alone for the treatment of postmenopausal women with overactive bladder syndrome.
Tseng LH; Wang AC; Chang YL; Soong YK; Lloyd LK; Ko YJ
Neurourol Urodyn; 2009; 28(1):47-51. PubMed ID: 19089890
[TBL] [Abstract][Full Text] [Related]
24. The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society.
North American Menopause Society
Menopause; 2007; 14(3 Pt 1):355-69; quiz 370-1. PubMed ID: 17438512
[TBL] [Abstract][Full Text] [Related]
25. [Local estrogen therapy--clinical implications--2012 update].
Kokot-Kierepa M; Bartuzi A; Kulik-Rechberger B; Rechberger T
Ginekol Pol; 2012 Oct; 83(10):772-7. PubMed ID: 23383564
[TBL] [Abstract][Full Text] [Related]
26. Hormonal, metabolic, and endometrial safety of testosterone vaginal cream versus estrogens for the treatment of vulvovaginal atrophy in postmenopausal women: a randomized, placebo-controlled study.
Fernandes T; Pedro AO; Baccaro LF; Costa-Paiva LH
Menopause; 2018 Jun; 25(6):641-647. PubMed ID: 29462095
[TBL] [Abstract][Full Text] [Related]
27. Fractional CO2 laser versus promestriene and lubricant in genitourinary syndrome of menopause: a randomized clinical trial.
Politano CA; Costa-Paiva L; Aguiar LB; Machado HC; Baccaro LF
Menopause; 2019 Aug; 26(8):833-840. PubMed ID: 31246661
[TBL] [Abstract][Full Text] [Related]
28. TX-004HR Improves Sexual Function as Measured by the Female Sexual Function Index in Postmenopausal Women With Vulvar and Vaginal Atrophy: The REJOICE Trial.
Kingsberg SA; Derogatis L; Simon JA; Constantine GD; Graham S; Bernick B; Gasper G; Mirkin S
J Sex Med; 2016 Dec; 13(12):1930-1937. PubMed ID: 27692842
[TBL] [Abstract][Full Text] [Related]
29. Most bothersome symptom in women with genitourinary syndrome of menopause as a moderator of treatment effects.
Pinkerton JV; Bushmakin AG; Abraham L; Cappelleri JC; Komm BS
Menopause; 2016 Oct; 23(10):1092-101. PubMed ID: 27404026
[TBL] [Abstract][Full Text] [Related]
30. Comparison of promestriene with vaginal fractional CO2 laser and radiofrequency treatments of genitourinary syndrome of menopause.
Seganfredo IB; Bianchi C; Tacla M; Chedraui P; Haddad JM; Simoes R; Baracat EC; Soares JM
Maturitas; 2024 Aug; 186():108008. PubMed ID: 38714422
[TBL] [Abstract][Full Text] [Related]
31. A multicenter, randomized, open, controlled trial to evaluate the efficacy of Honglilai Vaginal Cream and Premarin Vaginal Cream for Genitourinary Syndrome of Menopause in different subgroups of Chinese postmenopausal women.
Yang M; Lin S; Zheng S; Sun A; Bian M; Li S; Liu J; Hu L; Hui N; Zhong J; Hou H; Yue T; Gao X; Bai W
Gynecol Endocrinol; 2022 Oct; 38(10):861-867. PubMed ID: 36067791
[TBL] [Abstract][Full Text] [Related]
32. A survey of the therapeutic effects of Vitamin E suppositories on vaginal atrophy in postmenopausal women.
Parnan Emamverdikhan A; Golmakani N; Tabassi SA; Hassanzadeh M; Sharifi N; Shakeri MT
Iran J Nurs Midwifery Res; 2016; 21(5):475-481. PubMed ID: 27904630
[TBL] [Abstract][Full Text] [Related]
33. Intravaginal Testosterone Improves Sexual Satisfaction and Vaginal Symptoms Associated With Aromatase Inhibitors.
Davis SR; Robinson PJ; Jane F; White S; White M; Bell RJ
J Clin Endocrinol Metab; 2018 Nov; 103(11):4146-4154. PubMed ID: 30239842
[TBL] [Abstract][Full Text] [Related]
34. Identifying and treating sexual dysfunction in postmenopausal women: the role of estrogen.
Simon JA
J Womens Health (Larchmt); 2011 Oct; 20(10):1453-65. PubMed ID: 21819250
[TBL] [Abstract][Full Text] [Related]
35. Open, non-controlled clinical studies to assess the efficacy and safety of a medical device in form of gel topically and intravaginally used in postmenopausal women with genital atrophy.
Morali G; Polatti F; Metelitsa EN; Mascarucci P; Magnani P; Marrè GB
Arzneimittelforschung; 2006; 56(3):230-8. PubMed ID: 16618016
[TBL] [Abstract][Full Text] [Related]
36. Women's preferences toward attributes of local estrogen therapy for the treatment of vaginal atrophy.
Mattsson LÅ; Ericsson Å; Bøgelund M; Maamari R
Maturitas; 2013 Mar; 74(3):259-63. PubMed ID: 23312488
[TBL] [Abstract][Full Text] [Related]
37. Comparison of intravaginal 6.5mg (0.50%) prasterone, 0.3mg conjugated estrogens and 10μg estradiol on symptoms of vulvovaginal atrophy.
Archer DF; Labrie F; Montesino M; Martel C
J Steroid Biochem Mol Biol; 2017 Nov; 174():1-8. PubMed ID: 28323042
[TBL] [Abstract][Full Text] [Related]
38. Effect of one-week treatment with vaginal estrogen preparations on serum estrogen levels in postmenopausal women.
Labrie F; Cusan L; Gomez JL; Côté I; Bérubé R; Bélanger P; Martel C; Labrie C
Menopause; 2009; 16(1):30-6. PubMed ID: 18820592
[TBL] [Abstract][Full Text] [Related]
39. A comparative study of the effects of local estrogen with or without local testosterone on vulvovaginal and sexual dysfunction in postmenopausal women.
Raghunandan C; Agrawal S; Dubey P; Choudhury M; Jain A
J Sex Med; 2010 Mar; 7(3):1284-90. PubMed ID: 20102444
[TBL] [Abstract][Full Text] [Related]
40. Randomized, multicenter, double-blind, placebo-controlled trial to evaluate the efficacy and safety of synthetic conjugated estrogens B for the treatment of vulvovaginal atrophy in healthy postmenopausal women.
Simon JA; Reape KZ; Wininger S; Hait H
Fertil Steril; 2008 Oct; 90(4):1132-8. PubMed ID: 18053998
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
